Major indexes posted all-time closing highs Thursday as technology stocks surged following news that Nvidia will invest in ...

Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of ...

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock ...

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred ...

VIENNA (Reuters) -Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for ...

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...

Whether things are congenial or not, investors have little choice but to step into the arena, no matter what the economic backdrop. Under the current circumstances, sticking with a quality name in ...

Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

Novo Nordisk A/S (NYSE: NVO) is one of the best beginner stocks to buy, according to analysts. On September 17, Berenberg ...

Shares of D-Wave Quantum are higher by 35% over the past week. The recent rally is fueled by favorable macroeconomic ...